🔗 Share this article

While the United States undertakes historic changes to its vaccination schedules, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines throughout the global health crisis and has zeroed in on possible fatalities following COVID-19 immunization in her recent time at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Program

Agency leaders had intended to announce sweeping revisions to the pediatric vaccination calendar in December, aligning the US with the Danish vaccine program, it is understood – a substantial departure that would place the US at odds with a large portion of the global community with no evidence for improved outcomes. The planned update has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is set to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to run the center this calendar year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending some childhood shot schedules in the US to become more like Denmark's approach, a nation with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

To date statements, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

The appointee has no obvious background in pharmaceutical research, regulation or leadership, which has been typical for past directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for overseeing the CDER, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She lacks background in industry regulation.”

Former commissioners of the center would “grasp legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that previous people who headed CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and all of those need to be managed,” she noted. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial leadership element to the role, which manages more than 5,000 employees. “It’s a huge leadership role, if you execute it properly,” she concluded.

Response and Controversial Programs

When asked about concerns about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among agency officials on immunizations, a spokesperson said that the “concerns stem from inaccurate presumptions”.

“Her experience aligns with the duties of her job,” the spokesperson said, citing the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial expedited therapy clearance system that reportedly concerned her preceding directors. “By what process are these medications being chosen for this fast-track system? Who makes the decisions?” Howard said. “There is a lot of confidentiality happening at the agency right now.”

In general, he remarked, “the FDA looks to be trending towards more relaxed rules of all drugs, aside from immunizations.”

Documented Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, history, Howard said. She authored a analysis using unconfirmed public submissions to assess the frequency of myocarditis following Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership encompassed revising guidelines for new vaccines and ending “unnecessary” vaccines, she stated following the vote on a audio program. At the FDA, Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccines.

“She is an all-around true believer who begins with her beliefs and reverse-engineers to accommodate the evidence in a highly misleading, fraudulent fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow dissenters, {like|